American Society of Hematology

Figure 1.

$Figure 1. Design, characterization, and binding studies of the αCD20-IL-21 fusokine. (A) Expression cassette and structure of αCD20-IL-21 fusokine (left) and αCD20-IgG1 parent Ab control (right). (B) Immunoblotting of purified fractions of αCD20-IL-21 fusokine under reducing condition using αhIgG and αIL-21 Abs. (C and D) Flow cytometric analysis of binding of indicated Abs with CD20 or IL-21R expressed on 38C13-hCD20 and YB2/0 cells, respectively. Anti-hIgG-FITC was used as secondary (2°) mAb to detect cell bound Abs. CH1, CH2, CH3, constant region of human γ1 heavy chain; H, hinge region; L, 15-amino acid linker (SGGGG)3; V, variable region of αCD20.$

Design, characterization, and binding studies of the αCD20-IL-21 fusokine. (A) Expression cassette and structure of αCD20-IL-21 fusokine (left) and αCD20-IgG1 parent Ab control (right). (B) Immunoblotting of purified fractions of αCD20-IL-21 fusokine under reducing condition using αhIgG and αIL-21 Abs. (C and D) Flow cytometric analysis of binding of indicated Abs with CD20 or IL-21R expressed on 38C13-hCD20 and YB2/0 cells, respectively. Anti-hIgG-FITC was used as secondary (2°) mAb to detect cell bound Abs. CH1, CH2, CH3, constant region of human γ1 heavy chain; H, hinge region; L, 15-amino acid linker (SGGGG)₃; V, variable region of αCD20.

This Feature Is Available To Subscribers Only